Goldenwell Biotech, Inc.
GWLL · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -18.07 | 0.55 | -0.04 | -0.19 |
| FCF Yield | -0.62% | -2.03% | -3.77% | -0.76% |
| EV / EBITDA | -161.22 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | -55.37% | -51.58% | -398.84% | -33.84% |
| Gross Margin | 46.04% | 47.35% | 52.69% | 52.53% |
| Cash Conversion Ratio | 0.94 | 0.98 | 1.09 | 1.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -85.73% | -47.28% | – | – |
| Free Cash Flow Growth | -7.31% | 89.31% | -422.85% | -3,143.80% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | -14.65 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -5,369.19 |